David Loew, Ipsen CEO (via Twitter)
Failed deal, bidding war paved the way for Ipsen's $952M rare disease buyout
Ipsen may have a mysterious company to thank for its $952 million takeover of Albireo Pharma.
While the French pharma ultimately elbowed two potential buyers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
